Phase 3 studies and meta-analysis results in transplant-ineligible patients
| Study . | Treatment schema/duration . | No. of patients in treatment arm . | Median follow-up . | Best response . | PFS . | OS . |
|---|---|---|---|---|---|---|
| MPT meta-analysis*56 | MPT for 8 cycles, 12 cycles, or until relapse | 1685 (total no. of patients included) | Not available | VGPR: 25% | 20.3 mo | 39.3 mo |
| MPT (FIRST trial)74 | MPT for 12 cycles | 547 | 37 mo | CR: 9.3% | 21.2 mo | 4-y OS: 51.4% |
| CTD64 | CTD for up to 9 cycles (6 cycles minimum) | 426 | 44 mo | CR: 13.1% | 13 mo | 33.2 mo |
| VMP (VISTA trial)66 | VMP for 9 cycles | 344 | 60.1 mo | CR: 30% | 21.7 mo | 56.4 mo |
| MPR-R73 | MPR for 9 cycles, followed by R until disease progression | 152 | 30 mo | CR: 9.9% | 31 mo | 4-y OS: 59% |
| VMPT-VT67,69 | VMPT for 9 cycles, followed by VT for 2 y or until progression or relapse | 254 | 54 mo | CR: 38% | 35.3 mo | 5-y OS: 61% |
| VMP/VTP-VT68,70 | VMP or VTP for 6 cycles, followed by VT for up to 3 y | 91 | 46 mo | CR: 46% | 39 mo | 5-y OS: 69% |
| Rd continuous (FIRST trial)74 | Rd until disease progression | 535 | 37 mo | CR: 15.1% | 25.5 mo | 4-y OS: 59.4% |
| BP76 | BP until maximum remission or disease progression | 68 | Not available | CR: 32% | TTF: 14 mo | 32 mo |
| Study . | Treatment schema/duration . | No. of patients in treatment arm . | Median follow-up . | Best response . | PFS . | OS . |
|---|---|---|---|---|---|---|
| MPT meta-analysis*56 | MPT for 8 cycles, 12 cycles, or until relapse | 1685 (total no. of patients included) | Not available | VGPR: 25% | 20.3 mo | 39.3 mo |
| MPT (FIRST trial)74 | MPT for 12 cycles | 547 | 37 mo | CR: 9.3% | 21.2 mo | 4-y OS: 51.4% |
| CTD64 | CTD for up to 9 cycles (6 cycles minimum) | 426 | 44 mo | CR: 13.1% | 13 mo | 33.2 mo |
| VMP (VISTA trial)66 | VMP for 9 cycles | 344 | 60.1 mo | CR: 30% | 21.7 mo | 56.4 mo |
| MPR-R73 | MPR for 9 cycles, followed by R until disease progression | 152 | 30 mo | CR: 9.9% | 31 mo | 4-y OS: 59% |
| VMPT-VT67,69 | VMPT for 9 cycles, followed by VT for 2 y or until progression or relapse | 254 | 54 mo | CR: 38% | 35.3 mo | 5-y OS: 61% |
| VMP/VTP-VT68,70 | VMP or VTP for 6 cycles, followed by VT for up to 3 y | 91 | 46 mo | CR: 46% | 39 mo | 5-y OS: 69% |
| Rd continuous (FIRST trial)74 | Rd until disease progression | 535 | 37 mo | CR: 15.1% | 25.5 mo | 4-y OS: 59.4% |
| BP76 | BP until maximum remission or disease progression | 68 | Not available | CR: 32% | TTF: 14 mo | 32 mo |
MPR-R, melphalan-prednisone-lenalidomide-lenalidomide maintenance; TTF, time to treatment failure; VMPT-VT, bortezomib-melphalan-prednisone–thalidomide-bortezomib, thalidomide maintenance; VMP/VTP-VT, bortezomib-melphalan-prednisone/bortezomib-thalidomide-prednisone–bortezomib-thalidomide maintenance.
Meta-analysis based on individual data from 1685 patients included in 6 randomized trials.